A Phase 1 Multicenter Study of KITE-585, an Autologous Anti-BCMA CAR T-Cell Therapy, in Subjects With Relapsed/Refractory Multiple Myeloma

Trial Profile

A Phase 1 Multicenter Study of KITE-585, an Autologous Anti-BCMA CAR T-Cell Therapy, in Subjects With Relapsed/Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Apr 2018

At a glance

  • Drugs KITE 585 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man
  • Sponsors Kite Pharma
  • Most Recent Events

    • 03 Nov 2017 Status changed from not yet recruiting to recruiting.
    • 20 Oct 2017 Status changed to not yet recruiting.
    • 08 Aug 2017 According to a Kite Pharma media release, the company expects to initiate this study in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top